Research programme: coronavirus inhibitors - Fulcrum/Johns Hopkins UniversityAlternative Names: 3CLpro inhibitors; Coronavirus inhibitors research programme - Fulcrum/Johns Hopkins University; Coronavirus protease inhibitors
Latest Information Update: 13 Nov 2003
At a glance
- Originator Fulcrum Pharmaceuticals; Johns Hopkins University
- Mechanism of Action Peptide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Coronavirus infections
Most Recent Events
- 13 Nov 2003 Preclinical trials in Coronavirus infections in USA (unspecified route)